Our Blog Posts

While the majority of our research is reserved for clients only, Our blog is a great preview of our service. Note that our blog communicates only a small fraction of the amount of situations we follow and provide research on.
May 13, 2021
Renren Inc. (RENN) - Hearing on the Order to Show Cause.

A Hearing on the Order to Show Cause as to why Oak Pacific Investment (“OPI”) should not be restrained from Disposing (or any other related activity) of Social Finance, Inc. (“SoFi”) shares is currently scheduled to be held on Friday, May 14, 2021 at 9:30 AM ET in the Case of: “In Re RenRen, Inc. Derivative […]

Read More
January 19, 2021
Regeneron Pharmaceuticals, Inc. (REGN) - Overview of Regeneron's Litigation Pertaining to its Eylea® Product.

On January 15, 2021, the United States Patent & Trademark Office’s (“USPTO”) Patent Trial & Appeal Board (“PTAB”) issued a Decision that DENIED Institution of a Petition for Inter Partes Review filed by Regeneron, Inc. (REGN) against a Patent Owned by Novartis (NVS).  In light of this development, this email provides an overview of Regeneron’s remaining outstanding […]

Read More
December 8, 2020
Biogen, Inc. (BIIB) - Overview of the Appellate Cases in Advance of the Telephonic Oral Arguments.

On December 8, 2020, Telephonic Oral Arguments are currently scheduled to commence at 10:00 AM ET in the Appellate Cases of: “Mylan Pharmaceuticals Inc. v. Biogen MA Inc.” (Case #20-1673 at the Court of Appeals for the Federal Circuit) and “Biogen International GmbH v. Mylan Pharmaceuticals Inc.” (Case #20-1933 at the Court of Appeals for the Federal Circuit).  This […]

Read More
September 11, 2020
Corcept Therapeutics, Inc. (CORT) - Overview of the Outstanding Legal Catalysts Impacting Corcept's Korlym (Mifepristone) Drug.

On September 2, 2020, the Hearing in Teva’s “Post Grant Review” challenging Corcept’s U.S. Patent Number 10,195,214 (which covers Corcept’s Korlym product) was held before the United States Patent & Trademark Office’s (“USPTO”) Patent Trial & Appeal Board (“PTAB”).  This was in PGR2019-00048, and we now expect the PTAB to issue its Final Written Decision […]

Read More
- Note that blog posts represent our research as of the time of publishing, MDC makes no guarantee that the information presented will be updated in the future. See our disclosures for additional information.

We are not lawyers, and we do not practice law or render legal advice.  MDC Financial Research is a State-Registered Investment Advisor with Financial Analysts that approach legal situations from an investor angle for investment purposes. MDC Financial Research, LLC is currently registered in the States of California, Illinois, and New York.  Additional information and disclosures are contained in MDC Financial Research’s Form ADV and Form ADV Part 2 (Brochure).

Copyright © 2021, MDC Financial Research, LLC. All rights reserved.

Contact

MDC Financial Research, LLC
El Dorado Hills, CA
(510) 894-4476
Info@MDCFinancial.com